6 – 10 of 11
- show: 5
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2009
-
Mark
Vascular endothelial growth factor receptor 2 is a significant negative prognostic biomarker in triple-negative breast cancer: results from a controlled randomised trial of premenopausal breast cancer
(
- Contribution to journal › Published meeting abstract
-
Mark
Significantly higher expression of vascular endothelial growth factor (VEGF) and shorter survival after recurrences in premenopausal node negative patients with triple negative breast cancer
(
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
A randomized feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer
2008) EBCC-6, European Breast Cancer Conference, 2008 In European Journal of Cancer Supplements 6(7). p.116-117(
- Contribution to journal › Published meeting abstract
- 2003
-
Mark
Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer
(
- Contribution to journal › Article
- 2002
-
Mark
A population-based study on the first forty-eight breast cancer patients receiving trastuzumab (Herceptin (R)) on a named patient basis in Sweden
(
- Contribution to journal › Article